Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are in less than expected and cut revenue expectations for the year by US $9 billion.
Source: ctv business
Pfizer cuts full-year outlook due to declining sales of COVID-19-related products

